Blockade of chemokine signaling in patients with multiple sclerosis

F. Zipp, H. P. Hartung, J. Hillert, S. Schimrigk, C. Trebst, M. Stangel, C. Infante-Duarte, P. Jakobs, C. Wolf, R. Sandbrink, C. Pohl, M. Filippi

Research output: Contribution to journalArticle

Abstract

We assessed the safety and efficacy of orally administered CC chemokine receptor 1 (CCR1) antagonist in 105 patients with relapsing/remitting MS (RRMS) in a 16-week, randomized, double-blind, placebo-controlled trial. The primary endpoint was the cumulative number of newly active lesions on serial MRI scans. Other MRI, immunologic, and clinical outcomes were also explored. No significant treatment difference was observed for any tested MRI variable. CCR1 does not contribute to initial leukocyte infiltration in RRMS.

Original languageEnglish
Pages (from-to)1880-1883
Number of pages4
JournalNeurology
Volume67
Issue number10
DOIs
Publication statusPublished - Nov 2006

Fingerprint

CCR1 Receptors
Chemokines
Multiple Sclerosis
Leukocytes
Placebos
Magnetic Resonance Imaging
Safety
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Zipp, F., Hartung, H. P., Hillert, J., Schimrigk, S., Trebst, C., Stangel, M., ... Filippi, M. (2006). Blockade of chemokine signaling in patients with multiple sclerosis. Neurology, 67(10), 1880-1883. https://doi.org/10.1212/01.wnl.0000244420.68037.86

Blockade of chemokine signaling in patients with multiple sclerosis. / Zipp, F.; Hartung, H. P.; Hillert, J.; Schimrigk, S.; Trebst, C.; Stangel, M.; Infante-Duarte, C.; Jakobs, P.; Wolf, C.; Sandbrink, R.; Pohl, C.; Filippi, M.

In: Neurology, Vol. 67, No. 10, 11.2006, p. 1880-1883.

Research output: Contribution to journalArticle

Zipp, F, Hartung, HP, Hillert, J, Schimrigk, S, Trebst, C, Stangel, M, Infante-Duarte, C, Jakobs, P, Wolf, C, Sandbrink, R, Pohl, C & Filippi, M 2006, 'Blockade of chemokine signaling in patients with multiple sclerosis', Neurology, vol. 67, no. 10, pp. 1880-1883. https://doi.org/10.1212/01.wnl.0000244420.68037.86
Zipp F, Hartung HP, Hillert J, Schimrigk S, Trebst C, Stangel M et al. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology. 2006 Nov;67(10):1880-1883. https://doi.org/10.1212/01.wnl.0000244420.68037.86
Zipp, F. ; Hartung, H. P. ; Hillert, J. ; Schimrigk, S. ; Trebst, C. ; Stangel, M. ; Infante-Duarte, C. ; Jakobs, P. ; Wolf, C. ; Sandbrink, R. ; Pohl, C. ; Filippi, M. / Blockade of chemokine signaling in patients with multiple sclerosis. In: Neurology. 2006 ; Vol. 67, No. 10. pp. 1880-1883.
@article{4a775d76ccd14752955ad441d640253c,
title = "Blockade of chemokine signaling in patients with multiple sclerosis",
abstract = "We assessed the safety and efficacy of orally administered CC chemokine receptor 1 (CCR1) antagonist in 105 patients with relapsing/remitting MS (RRMS) in a 16-week, randomized, double-blind, placebo-controlled trial. The primary endpoint was the cumulative number of newly active lesions on serial MRI scans. Other MRI, immunologic, and clinical outcomes were also explored. No significant treatment difference was observed for any tested MRI variable. CCR1 does not contribute to initial leukocyte infiltration in RRMS.",
author = "F. Zipp and Hartung, {H. P.} and J. Hillert and S. Schimrigk and C. Trebst and M. Stangel and C. Infante-Duarte and P. Jakobs and C. Wolf and R. Sandbrink and C. Pohl and M. Filippi",
year = "2006",
month = "11",
doi = "10.1212/01.wnl.0000244420.68037.86",
language = "English",
volume = "67",
pages = "1880--1883",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Blockade of chemokine signaling in patients with multiple sclerosis

AU - Zipp, F.

AU - Hartung, H. P.

AU - Hillert, J.

AU - Schimrigk, S.

AU - Trebst, C.

AU - Stangel, M.

AU - Infante-Duarte, C.

AU - Jakobs, P.

AU - Wolf, C.

AU - Sandbrink, R.

AU - Pohl, C.

AU - Filippi, M.

PY - 2006/11

Y1 - 2006/11

N2 - We assessed the safety and efficacy of orally administered CC chemokine receptor 1 (CCR1) antagonist in 105 patients with relapsing/remitting MS (RRMS) in a 16-week, randomized, double-blind, placebo-controlled trial. The primary endpoint was the cumulative number of newly active lesions on serial MRI scans. Other MRI, immunologic, and clinical outcomes were also explored. No significant treatment difference was observed for any tested MRI variable. CCR1 does not contribute to initial leukocyte infiltration in RRMS.

AB - We assessed the safety and efficacy of orally administered CC chemokine receptor 1 (CCR1) antagonist in 105 patients with relapsing/remitting MS (RRMS) in a 16-week, randomized, double-blind, placebo-controlled trial. The primary endpoint was the cumulative number of newly active lesions on serial MRI scans. Other MRI, immunologic, and clinical outcomes were also explored. No significant treatment difference was observed for any tested MRI variable. CCR1 does not contribute to initial leukocyte infiltration in RRMS.

UR - http://www.scopus.com/inward/record.url?scp=33845458609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845458609&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000244420.68037.86

DO - 10.1212/01.wnl.0000244420.68037.86

M3 - Article

C2 - 17130431

AN - SCOPUS:33845458609

VL - 67

SP - 1880

EP - 1883

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 10

ER -